We are live on ! Find out more

Vanda Pharmaceuticals

VNDA

Market cap $242M

4.00 USD

+0.01

0.25%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

4.20

+0.20

5%

1 day

0.25%

5 days

-0.25%

1 month

-22.63%

3 months

-22.48%

6 months

-41.52%

Year to date

-51.52%

1 year

-28.32%

5 years

-77.52%

10 years

-73.15%

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Employees: 533

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15%

Neutral 65%

Negative 20%

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Vanda Pharmaceuticals NASDAQ: VNDA reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy purchasing and shipment timing. The company also said operating expenses declined 18% from the second quarter as certain late-stage development and launch-preparation activities concluded.

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Zacks Investment Research

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago.

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026 Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026 Announced positive results from the Phase III study of NEREUS™ for prevention of GLP-1-induced vomiting NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026 BYSANTI™ commercial launch expected in Q4 2026 Quimilza™ BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026 WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026. "We are pleased with the strong revenue growth in the third quarter, increasing 24% year-over-year, driven by continued Fanapt momentum and the early contribution from our NEREUS commercial launch, while operating expenses decreased 18% compared to the second quarter as key Phase III and launch-preparation activities conclude," said Mihael H.

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.

Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction Frequent multi-day vomiting (>2 episodes on more than one day): 6.3% (9/142) vs 15.9% (26/164) (p=0.008); 60% relative reduction Extreme vomiting (>10 total episodes): 2.8% (4/142) vs 14.6% (24/164) (p=0.0003); 81% relative reduction WASHINGTON, Oct. 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive results from Study 3601 (VP-VLY-686-3601), a Phase III randomized, placebo-controlled study evaluating NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting associated with GLP-1 receptor agonist therapy. The study showed significant reduction in overall vomiting episodes (27% p=0.006 as well as reduction of frequent (60% p=0.008) and extreme vomiting (81% p=0.0003) episodes.

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October 28, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2026, during which management will discuss the third quarter 2026 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline.

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Vanda Pharmaceuticals said on Wednesday its experimental drug for social anxiety disorder failed the main goal of a ‌late-stage study, prompting the company to put the program on hold pending further analysis of the data.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026. The following will be presented: Presentation Title: "Rapid reduction in neutrophils and neutrophil percentage-to-albumin ratio upon treatment with imsidolimab in patients with GPP" Abstract ID: AS-4323 Poster Number: P1769 Presentation Title: "Immunogenicity of Imsidolimab for the Treatment of Generalized Pustular Psoriasis (GPP)" Abstract ID: AS-2420 Poster Number: P1784 Presentation Title: "Imsidolimab Improves Generalized Pustular Psoriasis (GPP) Pustulation as Measured by the Pustulation Rating Scale (PRS): Results from the GEMINI-1 Study" Abstract ID: AS-2421 Poster Number: P2806 About Imsidolimab Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication.

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

See News Rankings

Price charts implemented using Lightweight Charts™